Transforming Growth Factors-β in Malignant Glioma: Preliminary Studies on Inhibition by Antisense Oligodeoxynucleotides

  • J. A. Koeppen
  • L. Owen-Schaub
  • E. A. Grimm
  • R. P. Moser
Conference paper
Part of the Advances in Neurosurgery book series (NEURO, volume 20)


Type β-transforming growth factors (TGF-β) are multifunctional polypeptides that regulate cell growth and differentiation. TGF-ß1 and TGF-β2 are closely related and resemble the immunosuppressive effects of malignant gliomas. As TGF-ß2 is produced by gliomas, it may contribute to glioma-mediated immunosuppression. To inhibit TGF-β production, a set of 16mer antisense oligodeoxynucleotides (ODNs) was constructed. The glioma cell line U-251 was incubated with 10 μM antisense oligodeoxynucleotides for 24 h. A specific antiproliferative effect was observed for an oligodeoxynucleotide complementary to a region of complete mRNA homology between TGF-ß1 and TGF-ß2. Inhibition of TGF-ß expression could not be verified in a standard Mv-1-Lu bioassay. In this assay TGF-ß inhibits proliferation of Mv-1-Lu cells. Direct treatment of Mv-1-Lu with TGF-ß1 and TGF-ß2 specific antisense as well as unspecific oligodeoxynucleotides resulted in a dose-dependent inhibition of proliferation, indicating direct and unspecific effects of these oligodeoxynucleotides on Mv-1-Lu.


Malignant Glioma Glioma Cell Line Lymphokine Activate Killer Antisense Oligodeoxynucleotides Antisense ODNs 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ausubel FM, Brent R, Kingstone KR, Moore DD, Seidmann JG, Smith JA, Strahl K (1987) Current protocols in molecular biology. John Wiley & Sons, New YorkGoogle Scholar
  2. 2.
    Fontana A, Hengartner H, De Tribolet N, Weber E (1984) Glioblastoma cells release interleukin-1 and factors inhibiting interleukin-2 mediated effects. J Immunol 132:1837–1844PubMedGoogle Scholar
  3. 3.
    Freier SM, Kierzek R, Jaeger JA, Sugimoto N, Caruthers MH, Neilson T, Turner DH (1986) Improved free-energy parameters for predictions of RNA duplex stability. Proc Natl Acad Sci USA 83:9373–9377PubMedCrossRefGoogle Scholar
  4. 4.
    Ignotz RA, Massague J (1987) Cell adhesion protein receptors as targets for transforming growth factor-beta action. Cell 51:189–197PubMedCrossRefGoogle Scholar
  5. 5.
    Jin B, Scott JL, Vadas MA, Burns GF (1989) TGF-beta down regulates TLiSAl expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells. Immunology 66:570–576PubMedGoogle Scholar
  6. 6.
    Kuppner MC, Hamou MF, Bodmer S, Fontana A, De Tribolet N N (1988) The glioblastoma derived T cell suppressor factor/transforming growth factor-B2 inhibits the generation of lymphokine activated killer (LAK) cells. Int J Cancer 42:562–567PubMedCrossRefGoogle Scholar
  7. 7.
    Maniatis T, Fritsch EF, Sambrook J (1982) Molecular cloning. Cold Spring Harbor, New YorkGoogle Scholar
  8. 8.
    Ponten J, Westermark B (1978) Properties of human malignant glioma in vitro. Medical Biology 56:184–193PubMedGoogle Scholar
  9. 9.
    Roszman TL, Brooks WH (1980) Immunobiology of primary intracranial tumours. III Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin Exp Immunol 38:395–402Google Scholar
  10. 10.
    Stein CA, Cohen JS (1988) Oligodeoxynucleotides as inhibitors of gene expression: A review. Cancer Res 48:2659–2668PubMedGoogle Scholar
  11. 11.
    Young HF, Sakalas R, Kaplan AM (1976) Inhibition of cell-mediated immunity in patients with brain tumors. Surg Neurol 5:19–23PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • J. A. Koeppen
    • 1
  • L. Owen-Schaub
    • 2
  • E. A. Grimm
    • 2
  • R. P. Moser
    • 2
  1. 1.Neurochirurgische AbteilungUniversitätskrankenhaus EppendorfHamburg 20Germany
  2. 2.M.D. Anderson Cancer CenterUniversity of TexasHoustonUSA

Personalised recommendations